We are live on ! Find out more
TRIB

Trinity Biotech

92 hedge funds and large institutions have $269M invested in Trinity Biotech in 2014 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 33 increasing their positions, 32 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

3% more capital invested

Capital invested by funds: $260M → $269M (+$8.64M)

3% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 32

0% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 15

3% less funds holding

Funds holding: 9592 (-3)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

37% less call options, than puts

Call options by funds: $492K | Put options by funds: $778K

Holders
92
Holders Change
-3
Holders Change %
-3.16%
% of All Funds
2.45%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.08%
New
15
Increased
33
Reduced
32
Closed
15
Calls
$492K
Puts
$778K
Net Calls
-$286K
Net Calls Change
+$240K
Name Holding Trade Value Shares
Change
Change in
Stake
RFC
26
Russell Frank Company
Washington
$3.42M +$462K +5,360 +16%
SC
27
Skylands Capital
Wisconsin
$3.4M +$605K +7,020 +22%
GA
28
Geneva Advisors
Illinois
$3.02M -$102K -1,186 -3%
Arrowstreet Capital
29
Arrowstreet Capital
Massachusetts
$2.64M -$320K -3,714 -11%
DGHMC
30
Dalton, Greiner, Hartman, Maher & Co
New York
$2.57M +$501K +5,810 +25%
SKK
31
Shepherd Kaplan Krochuk
Massachusetts
$2.47M +$138K +1,600 +6%
TA
32
Teton Advisors
New York
$2.4M
CCP
33
Centaur Capital Partners
Texas
$2.36M +$2.33M +27,000 New
KB
34
Kimelman & Baird
New York
$2.36M -$765K -8,880 -25%
TCM
35
Tamarack Capital Management
California
$2.19M +$2.15M +25,000 New
RHJA
36
Rice Hall James & Associates
California
$2.13M -$6.46K -75 -0.3%
TCM
37
Tygh Capital Management
Oregon
$1.76M +$432K +5,009 +33%
Two Sigma Investments
38
Two Sigma Investments
New York
$1.65M +$1.41M +16,322 +659%
GF
39
Gabelli Funds
New York
$1.39M +$862K +10,000 +169%
BCA
40
Benchmark Capital Advisors
New York
$1.27M +$22.4K +260 +2%
WIC
41
Woodmont Investment Counsel
Tennessee
$1.24M +$235K +2,725 +24%
KCM
42
Keane Capital Management
North Carolina
$1.22M -$5.17K -60 -0.4%
SM
43
Senvest Management
New York
$1.16M +$1.14M +13,247 New
PI
44
Putnam Investments
Massachusetts
$913K -$381K -4,419 -30%
Bank of New York Mellon
45
Bank of New York Mellon
New York
$889K +$184K +2,133 +27%
Citadel Advisors
46
Citadel Advisors
Florida
$823K +$169K +1,958 +26%
US Bancorp
47
US Bancorp
Minnesota
$794K -$228K -2,648 -23%
California Public Employees Retirement System
48
California Public Employees Retirement System
California
$741K
PCM
49
Prelude Capital Management
New York
$646K -$1.07M -12,428 -63%
WPC
50
White Pine Capital
Minnesota
$638K +$180K +2,090 +40%

TRIB Hedge Fund Activity: Q4 2014 in Review

92 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q4 2014, worth a combined $269M — up 3.3% from $260M a quarter earlier.

Fund positioning in TRIB was balanced in Q4 2014: 15 funds opened new positions, 15 closed out, 33 added to existing stakes and 32 trimmed.

The largest buyer was Kennedy Capital Management, adding an estimated $6.34M. The largest seller was Chartwell Investment Partners, exiting entirely with an estimated $10.2M sold.

  • 92 institutional investors held Trinity Biotech (TRIB) as of Q4 2014, down from 95 in Q3 2014.
  • Funds reported $269M of Trinity Biotech stock for Q4 2014, up 3.3% quarter-over-quarter.
  • 15 funds opened new Trinity Biotech positions in Q4 2014 and 15 closed out, a net change of 0 holders.
  • The largest Trinity Biotech buyer in Q4 2014 was Kennedy Capital Management, an estimated $6.34M added.
  • The largest Trinity Biotech seller in Q4 2014 was Chartwell Investment Partners, an estimated $10.2M sold.

Based on aggregated 13F filings for Q4 2014.